pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$HOOKHOOKIPA Pharma Inc.

$HOOK
New York, NY, USupdated 3mo ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 2: 1
1Phase 2
Phase 2
ninsipapogene sibarnarepvec
Head And Neck Squamous Cell Carcinoma (HNSC)

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view HOOKIPA Pharma Inc. jobs →

News

  • Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech
    → AbbVie and Boehringer Ingelheim’s Danish obesity partner Gubra is going with a co-CEO arrangement after the abrupt departure of Markus Rohrwild. Endpoints News just spoke with Rohrwild last month…
    endpoints · 4d ago
  • Windward prices $175M IPO to advance China-licensed lung drugs
    The Swiss biotech, which pocketed another $50 million through a concurrent private share sale to Sanofi, is developing a potential competitor to the blockbuster asthma treatment Tezspire.
    biopharma_dive · 4d ago
  • A new tactic in the war over out-of-network bills: Health care providers are suing employers
    Providers increasingly are suing employers, claiming they are responsible for out-of-network medical bills that insurers haven’t fully paid or have delayed paying.
    stat · 6d ago
  • ‘Flying blind’: Why experts fear Treasury’s China biotech investment crackdown will backfire
    The U.S. Treasury's COINS Act proposal aims to shield U.S. biotech from Chinese competition, but insiders warn it will backfire. As lawyers scramble to decipher an ambiguous ban on cross-border "jo…
    fiercebiotech · 10d ago
  • Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
    With companies including AstraZeneca, Pfizer and Revolution Medicines clamoring to get in on Summit Therapeutics’ Akeso-partnered PD-1xVEGF antibody, one analyst calls the asset “the next major bac…
    biospace · 15d ago
  • Labor Department finalizes sweeping PBM disclosure rule
    Starting in 2027, the controversial drug middlemen will have to share a broad swath of fee and compensation data with self-funded employer clients. Employers cheered the rule, while PBMs slammed it…
    biopharma_dive · 18d ago
  • Roche bets up to $813M on Zymeworks’ lung cancer trispecific T cell engager
    Roche will pay Zymeworks $55 million upfront plus another $40 million once the partnership asset enters Phase 1b development and up to $718 million in additional milestones.
    biospace · 25d ago
  • Ultragenyx's second PRV sale; Biomea's oral GLP-1 data leads to stock slump
    Plus news about United Therapeutics, Liquidia, Sanofi, Pharming, Skyhook Bio and Altay Therapeutics. Ultragenyx Pharmaceutical sells second PRV this month: The commercial-stage rare disease drugmak…
    endpoints · 1mo ago
  • Opinion: How states can resist the potential Trump vaccine shortages
    “States can serve as a last line of defense against the Trump administration’s anti-vaccine policy,” writes Joel Dodge.
    stat · 1mo ago
  • Zealand inks $1.2B Generate pact to add multispecific proteins to obesity pipeline
    Zealand Pharma is paying Generate Biomedicines $30 million upfront to collaborate on multispecific drug candidates for metabolic diseases. Milestones could bring the total value of the deal above $…
    fiercebiotech · 1mo ago
view all news mentions →
identifiers
ticker
$HOOK
SEC CIK
0001760542
country
US
source
sec_tickers
top tags
Oncology1
mentioned in
10news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 52m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?